CC BY-NC-ND 4.0 · Semin Thromb Hemost 2023; 49(06): 621-633
DOI: 10.1055/s-0042-1758818
Review Article

Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review

1   Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
2   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
3   Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada
4   Service of Benign Hematology, Hamilton Health Sciences, Hamilton General Hospital, Hamilton, Ontario, Canada
,
5   Institute for Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany
› Author Affiliations

Abstract

Heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT) are highly prothrombotic (thrombosis frequency ≥50%). Both are caused by platelet-activating anti-platelet factor 4 (PF4) antibodies, forming PF4/IgG-containing immune complexes that engage platelet FcγIIa receptors, producing strong platelet activation. In HIT, heparin crosslinks several PF4 molecules, whereas in VITT, anti-PF4 antibodies alone crosslink PF4. Sufficient levels of circulating anti-PF4 antibodies are needed to create the pathogenic immune complexes on platelet surfaces; this explains why certain serum (plasma)-based assays are highly sensitive for detecting HIT/VITT antibodies. Accordingly, HIT and VITT are “clinical-pathological” disorders, that is, positive testing for such antibodies—together with a compatible clinical picture—is integral for diagnosis. Heparin (low concentrations) enhances HIT antibody-induced platelet activation, but platelet activation by VITT sera is usually inhibited by heparin. For both HIT and VITT, high sensitivity (>99% and >95%, respectively) characterizes PF4-dependent enzyme immunoassays (EIAs) and PF4-enhanced platelet activation assays; in contrast, certain rapid immunoassays have high sensitivity for HIT (>90-97%) but poor sensitivity (<25%) for VITT. HIT and VITT antibodies are directed at distinct sites on PF4: solid-phase EIAs and platelet activation assays are indifferent to these distinct antigen targets, but rapid immunoassays are not. We discuss a conceptual model where PF4 is viewed as a “globe,” with the heparin-binding site the “equator”; in this model, HIT antibodies are primarily directed at antigen site(s) at the north and south “poles” of PF4 (formed when PF4 binds to heparin), whereas VITT antibodies recognize sites on the equator.



Publication History

Article published online:
01 December 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136 (03) 409-416
  • 2 Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982; 2 (8310): 1246-1249
  • 3 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67 (01) 27-30
  • 4 Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66 (06) 734-736
  • 5 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68 (01) 95-96
  • 6 Warkentin TE. Platelet-activating anti-PF4 disorders: an overview. Semin Hematol 2022; 59 (02) 59-71
  • 7 Warkentin TE, Greinacher A. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb Res 2021; 204: 40-51
  • 8 Favaloro EJ, Pasalic L, Lippi G. Antibodies against platelet factor 4 and their associated pathologies: from HIT/HITT to spontaneous HIT-like syndrome, to COVID-19, to VITT/TTS. Antibodies (Basel) 2022; 11 (01) 7
  • 9 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle P, Eichinger S. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101 . Preprint available at: https://assets.researchsquare.com/files/rs-362354/v2/c3d5df68-3cc0-40e4-a779-e19498b50d6f.pdf?c=1631880543
  • 10 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A. eds. Heparin-Induced Thrombocytopenia. 5th ed. Boca Raton, FL: CRC Press; 2013: 272-314
  • 11 Mayo KH, Ilyina E, Roongta V. et al. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. Biochem J 1995; 312 (Pt 2): 357-365
  • 12 Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71 (02) 247-251
  • 13 Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83 (11) 3232-3239
  • 14 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93 (01) 81-88
  • 15 Gollomp K, Kim M, Johnston I. et al. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight 2018; 3 (18) e99445
  • 16 Perdomo J, Leung HHL, Ahmadi Z. et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun 2019; 10 (01) 1322
  • 17 Kanack AJ, Bayas A, George G. et al. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood 2022; 140 (01) 73-77
  • 18 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344 (17) 1286-1292
  • 19 Warkentin TE, Sheppard JI, Whitlock RP. Temporal presentations of heparin-induced thrombocytopenia following cardiac surgery: a single-center, retrospective cohort study. J Thromb Haemost 2022; 20 (11) 2601-2616
  • 20 Warkentin TE. HITlights: a career perspective on heparin-induced thrombocytopenia. Am J Hematol 2012; 87 (Suppl 1): S92-S99
  • 21 Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15 (11) 2099-2114
  • 22 Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135 (07) 502-506
  • 23 Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 2016; 116 (05) 813-822
  • 24 Padmanabhan A, Jones CG, Pechauer SM. et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest 2017; 152 (03) 478-485
  • 25 Mian H, Warkentin TE, Sheppard JI. et al. Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood 2017; 130 (14) 1679-1682
  • 26 Refaai MA, Warkentin TE, Axelson M, Matevosyan K, Sarode R. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: a consequence of heparin “flushes”. Thromb Haemost 2007; 98 (05) 1139-1140
  • 27 Padmanabhan A, Jones CG, Bougie DW. et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood 2015; 125 (01) 155-161
  • 28 Cines DB, Yarovoi SV, Zaitsev SV. et al. Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. Blood Adv 2016; 1 (01) 62-74
  • 29 Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121 (07) 632-636
  • 30 Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT?. J Thromb Haemost 2008; 6 (09) 1598-1600
  • 31 Greinacher A, Langer F, Schönborn L. et al. Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica 2022; 107 (05) 1219-1221
  • 32 Shih AW, Sheppard JI, Warkentin TE. Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. Thromb Haemost 2017; 117 (10) 1868-1874
  • 33 Moores G, Warkentin TE, Farooqi MAM, Jevtic SD, Zeller MP, Perera KS. Spontaneous heparin-induced thrombocytopenia presenting as cerebral venous sinus thrombosis. Neurol Clin Pract 2021; 11 (06) e929-e931
  • 34 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
  • 35 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
  • 36 Scully M, Singh D, Lown R. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (23) 2202-2211
  • 37 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
  • 38 See I, Lale A, Marquez P. et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann Intern Med 2022; 175 (04) 513-522
  • 39 Herrera-Comoglio R, Lane S. Vaccine-induced immune thrombocytopenia and thrombosis after the Sputnik V vaccine. N Engl J Med 2022; 387 (15) 1431-1432
  • 40 Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). Accessed October 15, 2022 at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-TTS-2021.1
  • 41 Warkentin TE, Pai M. The epidemiology of thrombosis with thrombocytopenia syndrome: analogies with heparin-induced thrombocytopenia. Ann Intern Med 2022; 175 (04) 604-605
  • 42 Makris M, Pavord S. Most cases of thrombosis and thrombocytopenia syndrome (TTS) post ChAdOx1 nCov-19 are vaccine-induced immune thrombotic thrombocytopenia (VITT). Lancet Reg Health Eur 2021; 12: 100274
  • 43 Huynh A, Arnold DM, Michael JV. et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv 2023; 7 (02) 246-250
  • 44 Johansen S, Laegreid IJ, Ernstsen SL. et al. Thrombosis and thrombocytopenia after HPV vaccination. J Thromb Haemost 2022; 20 (03) 700-704
  • 45 Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 1998; 91 (03) 916-922
  • 46 Ziporen L, Li ZQ, Park KS. et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92 (09) 3250-3259
  • 47 Li ZQ, Liu W, Park KS. et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99 (04) 1230-1236
  • 48 Cai Z, Yarovoi SV, Zhu Z. et al. Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nat Commun 2015; 6: 8277
  • 49 Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596 (7873): 565-569
  • 50 Nguyen TH, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun 2017; 8: 14945
  • 51 Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113 (20) 4963-4969
  • 52 Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000; 96 (01) 182-187
  • 53 Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol 2019; 41 (Suppl 1): 15-25
  • 54 Schönborn L, Thiele T, Esefeld M. et al. Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies. J Thromb Haemost 2022; 20 (11) 2579-2586
  • 55 Greinacher A, Juhl D, Strobel U. et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5 (08) 1666-1673
  • 56 Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6 (08) 1304-1312
  • 57 Thiele T, Ulm L, Holtfreter S. et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood 2021; 138 (04) 299-303
  • 58 Barefah AS, Radhwi OO, Alamri SS. et al. Low clinical utility of testing for anti-platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoV-19 vaccine. Int J Lab Hematol 2022; 44 (02) 424-429
  • 59 Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976; 295 (05) 237-241
  • 60 Green D, Harris K, Reynolds N, Roberts M, Patterson R. Heparin immune thrombocytopenia: evidence for a heparin-platelet complex as the antigenic determinant. J Lab Clin Med 1978; 91 (01) 167-175
  • 61 Nelson JC, Lerner RG, Goldstein R, Cagin NA. Heparin-induced thrombocytopenia. Arch Intern Med 1978; 138 (04) 548-552
  • 62 Polgár J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998; 91 (02) 549-554
  • 63 Warkentin TE. How I diagnose and manage HIT. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 143-149
  • 64 Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol 2015; 90 (06) 564-572
  • 65 Eichler P, Budde U, Haas S. et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81 (04) 625-629
  • 66 Greinacher A, Gopinadhan M, Günther JU. et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26 (10) 2386-2393
  • 67 Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120 (03) 371-379
  • 68 Nazi I, Arnold DM, Warkentin TE, Smith JW, Staibano P, Kelton JG. Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. J Thromb Haemost 2015; 13 (10) 1900-1907
  • 69 Warkentin TE, Sheppard JI, Smith JW, Arnold DM, Nazy I. Timeline of heparin-induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay. Int J Lab Hematol 2019; 41 (04) 493-502
  • 70 Warkentin TE, Nazy I, Sheppard JI, Smith JW, Kelton JG, Arnold DM. Serotonin-release assay-negative heparin-induced thrombocytopenia. Am J Hematol 2020; 95 (01) 38-47
  • 71 Koster A, Nazy I, Birschmann IE, Smith JW, Sheppard JI, Warkentin TE. High-dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin-CPB in a patient with recent SRA-negative HIT-thrombosis with persisting platelet-activating antibodies. Res Pract Thromb Haemost 2020; 4 (06) 1060-1064
  • 72 Padmanabhan A, Jones CG, Bougie DW. et al. A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT. Thromb Haemost 2015; 114 (06) 1322-1323
  • 73 Padmanabhan A, Jones CG, Curtis BR. et al. A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis. Chest 2016; 150 (03) 506-515
  • 74 Vayne C, Guery EA, Kizlik-Masson C. et al. Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. Br J Haematol 2017; 179 (05) 811-819
  • 75 Greinacher A, Langer F, Makris M. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost 2022; 20 (01) 149-156
  • 76 Krauel K, Fürll B, Warkentin TE. et al. Heparin-induced thrombocytopenia–therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 6 (12) 2160-2167
  • 77 Warkentin TE, Greinacher A. Laboratory testing for VITT antibodies. Semin Hematol 2022; 59 (02) 80-88
  • 78 Handtke S, Wolff M, Zaninetti C. et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood 2021; 137 (26) 3656-3659
  • 79 Bourguignon A, Arnold DM, Warkentin TE. et al. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 385 (08) 720-728
  • 80 Vayne C, Rollin J, Gruel Y. et al. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385 (04) 376-378
  • 81 Thiele T, Weisser K, Schönborn L. et al. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. Lancet Reg Health Eur 2022; 12: 100270
  • 82 Uzun G, Althaus K, Singh A. et al. The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138 (11) 992-996
  • 83 Salih F, Schönborn L, Kohler S. et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med 2021; 385 (22) 2103-2105
  • 84 Kanack AJ, Singh B, George G. et al. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol 2022; 97 (05) 519-526
  • 85 Galea V, Khaterchi A, Robert F, Gerotziafas G, Hatmi M, Elalamy I. Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: confirmation in a prospective study. Platelets 2013; 24 (06) 441-447
  • 86 Morel-Kopp MC, Mullier F, Gkalea V. et al; Subcommittee on Platelet Immunology. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH. J Thromb Haemost 2016; 14 (12) 2548-2552
  • 87 Lee CSM, Liang HPH, Connor DE. et al. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Adv 2022; 6 (11) 3494-3506
  • 88 Lee CSM, Selvadurai MV, Pasalic L. et al. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. J Thromb Haemost 2022; 20 (04) 975-988
  • 89 Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113 (04) 886-890
  • 90 Warkentin TE, Sheppard JI, Moore JC, Kelton JG. The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8 (01) 216-218
  • 91 Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34 (05) 381-385
  • 92 Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95 (01) 161-167
  • 93 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67 (05) 545-549
  • 94 Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138 (01) 22-31
  • 95 Pouplard C, Leroux D, Regina S, Rollin J, Gruel Y. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103 (01) 145-150
  • 96 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; 121 (12) 1622-1627
  • 97 Platton S, Bartlett A, MacCallum P. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19 (08) 2007-2013
  • 98 Platton S, Schönborn L, Charrot S. et al. Vaccine-induced immune thrombocytopenia and thrombosis: the decline in anti-platelet factor 4 antibodies is assay-dependent. Br J Haematol 2022; 197 (04) 428-430
  • 99 Gabarin N, Arnold DM, Nazy I, Warkentin TE. Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol 2022; 59 (02) 89-96
  • 100 Gabarin N, Patterson S, Pai M. et al. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-1 vaccination. Thromb Haemost 2021; 121 (12) 1677-1680
  • 101 Nellen V, Sulzer I, Barizzi G, Lämmle B, Alberio L. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica 2012; 97 (01) 89-97
  • 102 Leroux D, Hezard N, Lebreton A. et al. Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2014; 166 (05) 774-782
  • 103 Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL® HIT-Ab(PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res 2017; 153: 108-117
  • 104 Althaus K, Hron G, Strobel U. et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res 2013; 131 (03) e85-e90
  • 105 Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood 2018; 132 (12) 1345-1349
  • 106 Vayne C, Nguyen TH, Rollin J. et al. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb Haemost 2021; 121 (03) 322-331
  • 107 Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93 (07) 2149-2157